Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Zielgerichtete Agonisten des Glucagon-ähnlichen Peptid-1-Rezeptors für Multiple Sklerose (TAG-MS)

9. November 2026 aktualisiert von: Johns Hopkins University

TAG-MS: Eine Phase-2-Studie zur gezielten Aktivierung von Glucagon-like-Peptide-1-Rezeptor-Agonisten bei Multipler Sklerose – randomisiert, doppelblind, mit parallelen Armen

The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).

Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

120

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Kansas
      • Kansas City, Kansas, Vereinigte Staaten, 66103
        • Rekrutierung
        • University of Kansas Medical Center
        • Hauptermittler:
          • Sharon Lynch, MD
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21287
        • Rekrutierung
        • Johns Hopkins University
        • Hauptermittler:
          • Ellen Mowry, MD, MCR
        • Kontakt:
    • New York
      • New York, New York, Vereinigte Staaten, 10029
        • Rekrutierung
        • Mount Sinai School of Medicine
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 60 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Diagnosis of MS (2024 criteria); clinically stable on MS therapy for ≥12 months without relapse or new lesions on brain MRI
  • Aged 18-60 years
  • Body mass index ≥27.0 kg/m2

Exclusion Criteria:

  • No GLP-1RA or GIP/GLP-1 RA in past year; no known hypersensitivity to medication class

  • No known Barrett's esophagus/gastroesophageal reflux disease, pancreatitis (including past), or gastroparesis

  • No personal/family history of medullary thyroid carcinoma or history of multiple endocrine neoplasia syndrome type 2

  • No chronic kidney disease (estimated glomerular filtration rate ≤50 mL/min) in past year, type 1 diabetes, known diabetic retinopathy, use of insulin or insulin-inducing medications*, dipeptidyl peptidase IV inhibitors**, or warfarin; current/active alcohol or illicit substance abuse

  • No concerns about candidacy of individual on part of person's neurologist or study team clinicians

  • Current or planned (next 2 years) pregnancy/breastfeeding; if able to become pregnant, agree to reliable contraception (contraception requirements as discussed below)***

    • currently-approved: Lispro, Aspart, Glulisine, Afrezza, Regular, Concentrated Regular, or Novolin, Velosulin, NPH, glargine, detemir, degludec, and premixed; approved secretagogues: sulphonylureas (e.g. glipizide (± metformin), glyburide (± metformin), glimepiride, pioglitazone/glimepiride) & meglitinide analogues (nateglinide and repaglinide); ** currently-approved:sitagliptin, saxagliptin, linagliptin, alogliptin ***Contraception: Participants of childbearing potential (participant has a uterus and is pre-menopausal) must agree to use contraception, using either one method with a failure rate of <1%/year, or two methods of lesser effectiveness:

Contraceptive methods with a failure rate of < 1% per year includes the following:

  • Combined (estrogen and progesterone containing) hormonal contraception (vaginal ring, birth control patch) or progesterone-only hormonal contraception (birth control injections, intrauterine device (IUD), or hormone-releasing implant), or copper IUD
  • Complete abstinence from sexual encounters with a person who has testes

Those who do not wish to use one of the above methods of contraception must use two methods. Options include:

  • Oral hormonal contraception plus one barrier method during sexual encounter with a person who has testes (below). While typically oral hormonal contraception has a low failure rate, it is possible that the absorption of contraceptive pills taken by mouth will be impacted by the study drug and thus lower contraceptive effectiveness. Thus, people using pills as primary contraception must, during asexual encounter with a person who has testes, use a second form of barrier contraceptive (below) or must change to one of the other contraceptive methods listed above.

  • Two forms of barrier contraception during sexual encounter with a person who has testes. Examples of barrier contraceptive methods include the following:

    • A condom with or without spermicide

    • A cap, diaphragm, or sponge with or without spermicide

      • Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Placebo

Placebo (saline solution)

Aktiver Komparator: NLY01 (Study Drug)

5 mg subcutaneous weekly for the first 4 weeks, then 10 mg subcutaneous weekly, with pre-planned dose adjustments if adverse events prevent full dosage.

NLY01 is a pegylated exenatide

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in normalized (for head size) brain parenchymal volume (nBPV)
Zeitfenster: Baseline, week 48, and week 96

Change in normalized (for head size) nBPV (mL). Measured from randomization to end of treatment (approximately 96 weeks). Presented as mean and standard deviation

Baseline, week 48, and week 96

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in normalized gray matter volume (mL)
Zeitfenster: Baseline, week 48, and week 96

Presented as mean and standard deviation Measured from randomization to end of treatment (approximately 96 weeks).

Baseline, week 48, and week 96
Change in thalamic volume (mL)
Zeitfenster: Baseline, week 48, and week 96

Measured from randomization to end of treatment (up to 96 weeks). Presented as mean and standard deviation.

Baseline, week 48, and week 96
Change in cortical thickness (mm)
Zeitfenster: Baseline, week 48, and week 96

Measured from randomization to end of treatment (approximately 96 weeks), Presented as mean and standard deviation.

Baseline, week 48, and week 96
Change in retinal nerve fiber layer thickness
Zeitfenster: Baseline, week 48, and week 96

Measured in μm, from randomization to end of treatment (approximately 96 weeks),

Baseline, week 48, and week 96
Change in ganglion cell/inner plexiform thickness
Zeitfenster: Baseline, week 48, and week 96

Measured in μm, from randomization to end of treatment (approximately 96 weeks),

Baseline, week 48, and week 96
Disability progression as assessed by the Expanded Disability Status Scale (EDSS)
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Expanded Disability Status Scale (EDSS). Scale range 0-10; higher score is worse disability progression

Approximately every 24 weeks, up to 96 weeks
Disability progression as assessed by the Multiple Sclerosis Functional Composite (MSFC)
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

The Multiple Sclerosis Functional Composite (MSFC) calculates a single Z-score from tests of ambulation, arm dexterity, and cognition. Scores are converted to a z score with a mean and standard deviation. A higher Z-score indicates better function.

Approximately every 24 weeks, up to 96 weeks
Disability progression as assessed by the Expanded Disability Status Scale-Plus
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

The EDSS-plus allows for documentation of progression as a composite value, considering progression as having occurred if any one of the following occurs: 20% increase in timed 25-foot walk or 9-hole peg test, or a 1.0-point increase in EDSS (if baseline is 5.5 or less) or a 0.5-point increase (if baseline is >5.5).

Approximately every 24 weeks, up to 96 weeks
Patient-reported disability progression as assessed by the Patient-Determined Disease Steps
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Patient-Determined Disease Steps score range 0-8; higher is worse progression

Approximately every 24 weeks, up to 96 weeks
Change in self-reported anxiety as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported depression as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported fatigue as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported upper extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported lower extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported cognitive function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in positive affect/well-being as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported sleep disturbance as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported ability to participate in social roles Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported stigma as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Adverse events
Zeitfenster: From randomization to week 96

Proportion of individuals in each arm experiencing adverse events

From randomization to week 96
Serious adverse events
Zeitfenster: From randomization to week 96

Proportion of individuals in each arm experiencing serious adverse events

From randomization to week 96

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Ellen M Mowry, MD, MCR, Johns Hopkins University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

28. April 2026

Primärer Abschluss (Geschätzt)

1. Januar 2030

Studienabschluss (Geschätzt)

1. Januar 2030

Studienanmeldedaten

Zuerst eingereicht

11. März 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

24. März 2026

Zuerst gepostet (Tatsächlich)

27. März 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

10. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • IRB00454859

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

De-identified individual participant data (IPD) that underlie the results reported in this publication, along with the protocol and analysis plan, will be available upon reasonable request to qualified researchers. Requests must include a proposal and are contingent on meeting regulatory approvals, including a signed data use agreement.

IPD-Sharing-Zeitrahmen

Data will be available 6 months after publication and remain accessible for 12-24 months.

IPD-Sharing-Zugriffskriterien

Qualified researchers who have completed and signed approvals for data sharing.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .